
News
Advertisement


Advertisement




Advertisement


















ICYMI: Denise Visco, MD, shares the take-home message from her 2019 ASCRS presentation.


A new therapy is being investigated in a phase IIb trial to test its safety and effectiveness in patients with moderate-to-severe dry eye disease.



Phase III studies of a gene therapy for Leber Hereditary Optic Neuropathy have generated some unexpected positive findings. There is biologic plausibility to explain the data.
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
The Residency Report: Cardiovascular risk scores as a window into ocular disease
4
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
5

